Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary research, review and
news journal. One of its main aims is to assure rapid publication of authoritative reviews and research papers dealing with experimental
and clinical aspects of neuro-psychopharmacology and biological psychiatry. Another important ... click here for full Aims & Scope
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary research, review and
news journal. One of its main aims is to assure rapid publication of authoritative reviews and research papers dealing with experimental
and clinical aspects of neuro-psychopharmacology and biological psychiatry. Another important aim of the journal is to supply pertinent
information, provided by national and international bodies, that contributes to progress in the scientific and professional fields. Finally,
the journal intends to foster and encourage communications between members of the communities of neuro-psychopharmacology and biological
psychiatry.
US National Institutes of Health (NIH) voluntary posting ("Public Access") policy
Progress in Neuropsychopharmacology & Biological Psychiatry and Elsevier facilitate the author's response to the NIH Public Access Policy. For more details please
see the Guide for authors
Fraudulent 'phishing' e-mails soliciting scholarly papers have been circulating which claim to originate from Elsevier, Inc.
and are directed to prospective authors and editors.
The fraudulent e-mail messages currently in circulation generally contain
"Manuscript Submission" or "Call for Papers" in the subject line and are typically sent using e-mail accounts supported by Gmail, Hotmail
or by other free e-mail providers. Typically, the body of these messages contain a "Call for Papers," requesting that authors submit
scholarly articles via e-mail for publication by Elsevier in various Elsevier journals and other publications. Ultimately, these fraudulent
e-mails involve a request for the victims to send "handling fees" to cover the processing of the article that has been submitted.
Please be assured that Elsevier, Inc. is in no way associated with this fraudulent e-mail campaign. In addition, please be advised
that Elsevier does not solicit intellectual property from authors in this fashion, and does not utilize Gmail, Hotmail,
or any other free third-party e-mail providers in communications with authors and editors.
If you receive any e-mail messages that
appear to be a part of this fraudulent solicitation, DO NOT respond to the message and do not open any attachments contained
in the message. Rather, please forward the message to Elsevier's Fraud Department at emailabuse@elsevier.com. We will
use the information included in the message to aid in our investigation.
Hide Aims & Scope
Editor-in-Chief:
Guy Drolet
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company